UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000046189
Receipt number R000052681
Scientific Title A study on the effect of continuous intake of test foods on immune function. -a randomized, placebo-controlled, double-blind, parallel-group comparison trial-
Date of disclosure of the study information 2022/11/28
Last modified on 2024/05/16 16:06:52

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A study on the effect of continuous intake of test foods on immune function. -a randomized, placebo-controlled, double-blind, parallel-group comparison trial-

Acronym

A study on the effect of continuous intake of test foods on immune function.

Scientific Title

A study on the effect of continuous intake of test foods on immune function. -a randomized, placebo-controlled, double-blind, parallel-group comparison trial-

Scientific Title:Acronym

A study on the effect of continuous intake of test foods on immune function.

Region

Japan


Condition

Condition

Healthy adults

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

This study aims to investigate the effect of continuous intake of test foods for 12 weeks on immune function and physical condition in healthy males and females aged between 20 and less than 65 years old.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Physical condition questionnaire

Key secondary outcomes

QoL questionnaire
Immune function-related biomarkers


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Take two capsules of the placebo food after breakfast once every day

Interventions/Control_2

Take two capsules of the test food after breakfast once every day

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

65 years-old >

Gender

Male and Female

Key inclusion criteria

1. Aged between 20 and less than 65 years old.
2. Japanese males and females.
3. Individuals who contract the common cold between winter and spring every year.
4. BMI between 17.5 kg/m^2 and less than 30.0 kg/m^2.
5. Individuals who can use smartphones or PCs to input an electronic diary.
6. Individuals who received sufficient explanation for the objective and summary of the trial, and voluntarily volunteered to the trial with the agreement of informed consent.

Key exclusion criteria

1. Individuals who have mouth dryness, or hypersalivation.
2. Individuals who are currently undergoing treatment for any disease with medical drugs or traditional Chinese medicines.
3. Individuals who are managed by medical doctors for diet/exercise therapy.
4. Individuals who have severe diseases or a history of severe diseases.
5. Individuals who have allergic dermatitis, allergic rhinitis, bronchial asthma, or chronic bronchitis.
6. Individuals who have been taking yogurts or beverages, which include Lactic acid bacteria and/or Bifidobacterium. However, individuals who can discontinue taking these foods during the trial will be allowed.
7. Individuals who have currently been taking commercially available drugs, quasi-drug products, and foods or supplements with functional claims. However, who can discontinue taking these materials during the trial will be allowed.
8. Individuals who have a drug/food allergy.
9. Individuals who work in shift, night shift.
10. Individuals who are planning extremely change their lifestyle during the trial.
11. Individuals who drink more than 60 g alcohol/day.
12. Individuals who have been vaccinated to protect against infectious disease one month before this study. Also, planning vaccination during the trial period.
13. Individuals who are planning travel to foreign countries during the trial.
14. Individuals who are pregnant or breastfeeding. Also, planning to pregnant during the trial period.
15. Individuals who joined other clinical trials from 1 month before this trial, or those who have currently been joined or planning to join other clinical trials.
16. Individuals who donated blood more than 200 mL within one month, or more than 400 mL within three months before the screening period.
17. Individuals who cannot discontinue taking alcoholic drinks two days before the date of visit.
18. Individuals who are unsuitable for this trial, that judged by the principal investigator.

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Norihisa
Middle name
Last name Nishida

Organization

Kobelco Eco-Solutions Co.,Ltd.

Division name

Algae Business Promotion Department

Zip code

651-0072

Address

1-4-78, Wakinohama-cho, Chuo-ku, Kobe-shi, Hyogo, Japan

TEL

078-232-8384

Email

nishida.norihisa@kobelco.com


Public contact

Name of contact person

1st name Yoshitada
Middle name
Last name Hira

Organization

IMEQRD Co., Ltd.

Division name

Planning and Sales Department

Zip code

104-0061

Address

Daiwa Ginza Bld. 3F, 6-2-1, Ginza, Chuo-ku, Tokyo

TEL

03-6704-5968

Homepage URL


Email

clinical-trial@imeqrd.co.jp


Sponsor or person

Institute

IMEQRD Co., Ltd.

Institute

Department

Personal name



Funding Source

Organization

Kobelco Eco-Solutions Co.,Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Suda Clinic institutional review board

Address

2-8-14,Takadanobaba,Shinjyuku,Tokyo

Tel

03-6704-5968

Email

jimukyoku@imeqrd.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2022 Year 11 Month 28 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

100

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2021 Year 11 Month 15 Day

Date of IRB

2021 Year 11 Month 24 Day

Anticipated trial start date

2022 Year 01 Month 31 Day

Last follow-up date

2022 Year 04 Month 28 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2021 Year 11 Month 26 Day

Last modified on

2024 Year 05 Month 16 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000052681